Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Vision 2030 accelerating patient access to innovative treatments, says SFDA chief

SFDA CEO Hisham Aljadhey highlights Vision 2030’s role in speeding access to new therapies and prioritizing patient protection at a global regulatory summit.

Vision 2030 accelerating patient access to innovative treatments, says SFDA chief

Hisham Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA), underscored the significance of Vision 2030 in expediting access to novel therapies and safeguarding patient interests at a global regulatory conference. The Saudi regulator stressed the necessity of bolstering cooperation among international regulatory agencies and harnessing innovation to establish regulatory systems.

Aljadhey highlighted that these collaborative efforts are crucial for keeping up with the swift advancements in the pharmaceutical industry and swiftly delivering novel treatments suited for patients, particularly those afflicted by rare ailments and necessitating specialized treatments. As reported by the authority, Aljadhey delivered these insights during a panel discussion titled 'Shared Leadership: Shaping the Future of Global Regulatory Systems through Collaboration and Regulatory Innovation,' which took place during the DIA-MHRA Global Summit in London on November 16 and 17.

He elaborated that, pursuant to Saudi Vision 2030, the nation is progressively constructing a cohesive and enduring regulatory framework that heightens oversight efficacy, anticipates obstacles, and adjusts to evolving circumstances. Patient safety remains the utmost priority by guaranteeing access to secure and efficacious medical products that fulfill healthcare requisites.

Aljadhey emphasized that Saudi Arabia's advancements in regulatory affairs are a result of nationwide collaboration, investments in research and innovation, incorporation of cutting-edge technologies in the production and development of biopharmaceuticals, and enlargement of data infrastructure. These initiatives have fortified the healthcare domain and refined regulatory assessment methodologies in harmony with scientific and technological progress in the pharmaceutical sector.

The SFDA's involvement in the summit underscores the authority's persistent role in elevating Saudi Arabia's standing in global regulatory platforms and its commitment to influencing the future trajectory of pharmaceutical oversight. This is accomplished through the exchange of expertise and best practices with comparable organizations and fostering innovation in medical product development, thereby enhancing patient safety and the availability of secure and efficacious treatments.

Written by urgent.news from Ajel English's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at english.ajel.sa →

More in Health & Medicine

More from Wednesday 18 November →